How AI and Precision Diagnostics Are Shaping Multiplexed Diagnostic Assays According to a newly published market research report by 24LifeSciences, the global high-density multiplexed diagnostic assays market was valued at USD 1,617 million in 2026 and is projected to reach USD 3,878 million by 2034, growing at a compound annual growth rate (CAGR) of 13.6% during the forecast period. High-density multiplexed diagnostic assays are sophisticated laboratory techniques capable of simultaneously measuring dozens to thousands of analytes from a single, minimal sample volume. These assays represent a paradigm shift in diagnostic capabilities, offering comprehensive profiling that conserves time, reagents, and precious biological samples. Powered by advanced technologies including microarray platforms, bead-based arrays, and next-generation sequencing (NGS), these tools are revolutionizing diagnostics across immunology, oncology, infectious diseases, and biomarker discovery. Their ability to deliver extensive data from one test run is transforming how clinicians and researchers approach complex disease profiling and personalized medicine. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9125/high-density-multiplexed-diagnostic-assays-market

Non-Sterile Compounding Pharmacy Market Outlook 2025–2032: Size, Trends & Players According to a newly published market research report by 24LifeSciences, global non-sterile compounding pharmacy market is valued at USD 595 million in 2026 and is projected to reach USD 694 million by 2034, growing at a compound annual growth rate (CAGR) of 2.3% during the forecast period. Non-sterile compounding involves the customized preparation of medications for oral, topical, nasal, otic, or rectal administration, tailored to meet specific patient needs unavailable in commercial formulations. This practice requires strict adherence to regulatory standards like USP Chapter <795>, ensuring product integrity, accurate dosing, and patient safety. Its critical role in personalized medicine makes it indispensable for populations requiring unique formulations, including pediatric, geriatric, and patients with allergies or sensitivities to standard drug excipients. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9556/non-sterile-compounding-pharmacy-market

How Personalized Medicine Is Shaping the Future of Retinoblastoma Treatment According to a newly published market research report by 24LifeSciences, global retinoblastoma treatment market value is at USD 82.1 million in 2026 and is projected to reach USD 112.7 million by 2032, growing at a compound annual growth rate (CAGR) of 5.9% during the forecast period. Retinoblastoma is a rare pediatric eye cancer that primarily affects children under five years old, originating in the retina. This malignancy presents significant treatment challenges due to its occurrence in very young patients and the critical need to preserve vision whenever possible. The treatment landscape is highly specialized, incorporating chemotherapy, radiation therapy, laser therapy, cryotherapy, and surgical interventions. Recent advances in superselective intra-arterial chemotherapy and intravitreal chemotherapy have revolutionized care by delivering targeted treatment directly to the tumor site, maximizing efficacy while minimizing systemic side effects. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9358/retinoblastoma-treatment-market

Personalized Medicine Trends in the Ophthalmic Therapeutics & Drug Market According to a newly published market research report by 24LifeSciences, global ophthalmic therapeutics & drug market was valued at USD 33.92 billion in 2024 and is projected to reach USD 51.2 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.1% during the forecast period 2025–2032. Ophthalmic therapeutics and drugs are specialized pharmaceutical products designed to treat a wide spectrum of eye diseases and disorders. These critical medications are formulated for topical administration, such as eye drops and ointments, or for invasive procedures like intravitreal injections, targeting conditions from common ailments like dry eye and allergies to serious, vision-threatening diseases such as age-related macular degeneration (AMD), glaucoma, and diabetic retinopathy. Key therapeutic classes include anti-allergy, anti-VEGF agents, anti-inflammatory, and anti-glaucoma medications. Their established efficacy in preserving vision and managing ocular health continues to underpin their critical importance in both clinical ophthalmology and global public health initiatives. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9401/ophthalmic-therapeutics-drug-market

Patient Derived Xenograft (PDX) Models Market Size to Reach USD 653 Million by 2032 Global Patient Derived Xenograft (PDX) Models market is witnessing strong momentum as precision oncology and personalized medicine reshape cancer drug development worldwide. Valued at USD 358 million in 2024, the market is projected to reach USD 653 million by 2032, expanding at a robust CAGR of 9.2% during the forecast period. Increasing demand for highly predictive preclinical models, coupled with rising oncology R&D investment, continues to position PDX models as a cornerstone of modern translational cancer research. Access the market report https://www.24lifesciences.com/patient-derived-xenograft-pdx-models-market-9495

𝗚𝗹𝗼𝗯𝗮𝗹 𝟯𝗗 𝗣𝗿𝗶𝗻𝘁𝗶𝗻𝗴 𝗶𝗻 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 & 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗦𝗲𝘁 𝘁𝗼 𝗦𝘂𝗿𝗽𝗮𝘀𝘀 𝗨𝗦𝗗 𝟭𝟬 𝗕𝗶𝗹𝗹𝗶𝗼𝗻 𝗯𝘆 𝟮𝟬𝟯𝟮 𝙁𝙚𝙚𝙡 𝙁𝙧𝙚𝙚 𝙏𝙤 𝙀𝙭𝙥𝙡𝙤��𝙚 𝙊𝙪𝙧 𝙁𝙧𝙚𝙚 𝙎𝙖𝙢𝙥𝙡𝙚 𝙍𝙚𝙥𝙤𝙧𝙩: https://bit.ly/3LTQ5wL The global 3D Printing Medical/Healthcare Market is entering a transformative phase, reshaping patient care through personalized, precision-driven medical solutions. Valued at USD 3.07 billion in 2024, the market is projected to expand rapidly from USD 3.79 billion in 2025 to USD 10.82 billion by 2032, registering a strong 16.7% CAGR during the forecast period. This acceleration is fueled by the growing adoption of personalized medicine, rising demand for patient-specific implants and prosthetics, and continuous breakthroughs in bioprinting technologies. Regulatory momentum, including recent FDA clearances for 3D-printed medical devices, alongside strategic acquisitions by industry leaders, is further validating the clinical viability of additive manufacturing in healthcare.